Condition: NSCLC, Stage III · Locally Advanced Lung Carcinoma · Sponsor: Jun Zhang, MD, PhD
This phase IV study is hoping to determine if examining the microbiome in non-small cell lung cancer participants who will receive durvalumab can predict treatment toxicity.
This description comes directly from the study's public registry record.
KUCC Navigation · 9135883671 · kucc_Navigation@kumc.edu
Always discuss trial participation with your own doctor first.
| The University of Kansas Cancer Center, Westwood Campus | Kansas City, Kansas, United States | Recruiting |
| Rhode Island Hospital, Brown University | Providence, Rhode Island, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04680377